Edema factor (EF) and CyaA are adenyl cyclase toxins secreted by pathogenic bacteria that cause anthrax and whooping cough, respectively. Using the structure of the catalytic site of EF, we screened a database of commercially available, small molecular weight chemicals for those that could specifically inhibit adenyl cyclase activity of EF. From 24 compounds tested, we have identified one quinazoline compound, ethyl 5-aminopyrazolo[1,5-α]quinazoline-3-carboxylate, that specifically inhibits adenyl cyclase activity of EF and CyaA with ~20 μM Kᵢ. This compound neither affects the activity of host resident adenyl cyclases type I, II, and V nor exhibits promiscuous inhibition. The compound is a competitive inhibitor, consistent with the prediction that it binds to the adenine portion of the ATP binding site on EF. EF is activated by the host calcium sensor, calmodulin. Surface plasmon resonance spectroscopic analysis shows that this compound does not affect the binding of calmodulin to EF. This compound is dissimilar from a previously described, non-nucleoside inhibitor of host adenyl cyclase. It may serve as a lead to design antagonists to address the role of adenyl cyclase toxins in bacterial pathogenesis and to fight against anthrax and whooping cough.

The 2001 anthrax attacks in the United States have spurred an intense effort to discover new drugs to combat this dangerous biowarfare agent (1). Anthrax is caused by the pathogenic bacterium Bacillus anthracis. The anthrax bacterium secretes three major exotoxins, protective antigen (PA),1 lethal factor (LF), and edema factor (EF) (2). PA is a pH-dependent transporter that delivers LF and EF into host cells. To do so, 83-kDa PA (PA₈₃) first associates with the cell surface protein tumor endothelial marker 8 (TEM-8) (3). The N-terminal 20-kDa domain of PA₈₃ is then cleaved by a surface furin-like protease to form a PA₆₃ heptamer. Two PA₆₃ domains within the PA₆₃ heptamer form a surface to bind an EF or LF molecule so that up to 3 mol of EF/LF mixtures can be delivered by a PA₆₃ heptamer (4). Upon endocytosis and acidification, PA forms a pore to deliver EF or LF into the cytosol of host cells (5). EF is a calmodulin (CaM)-activated adenyl cyclase that can elevate intracellular cAMP to pathological levels (6). LF is a metalloprotease that can cleave and inactivate a family of mitogen-activated kinase kinases including mitogen-activated protein kinase/extracellular signal-regulated kinase and p38 kinase (7, 8). All three toxins work in concert with a poly-o-glutamate capsule to make the anthrax bacterium deadly (9).

The molecular structures of all three anthrax toxins have been determined recently, providing an excellent starting point to develop specific inhibitors against the action of these toxins (6, 10, 11). Several peptide-based reagents including the extracellular domain of TEM-8, dominant-negative PA mutants, and oligomers of PA-binding peptides have been developed to block PA from interacting with TEM-8, forming a functional pore, and associating with EF/LF, respectively (3, 12, 13). In addition, sensitive assays to search for LF inhibitors and low nanomolar affinity inhibitors of LF have been developed recently (14, 15). However, to date no inhibitor against EF has been identified.

We have determined the molecular structure of EF with and without CaM (6). Based on the structure of EF, we have found that the catalytic site of this enzyme is different from host adenyl cyclases. This contrast suggests that it should be feasible to identify small molecular weight compounds that can specifically inhibit the activity of EF without affecting host adenyl cyclases. The deletion of the EF gene in B. anthracis not only impairs the germination of the anthrax bacterium in mouse peritoneal macrophages but also raises the LD₅₀ value by 2 orders of magnitude in a rodent model (16, 17). These results suggest that the blockage of adenyl cyclase activity of EF may significantly reduce the lethality of anthrax bacterium, thereby providing a wider window to treat patients with anthrax infection. The adenyl cyclase domain of EF also shares homology with other adenyl cyclase toxins, CyaA and ExoY (18, 19). CyaA is vital for the colonization of Bordetella pertus-

1–393); TEM, tumor endothelial marker; mAC, mammalian adenyl cyclase.
sis in the respiratory tract; successful colonization results in whooping cough, a major health threat to infants (20). ExoY is a toxin delivered by the type III secretion system of *Pseudomonas aeruginosa,* a bacterium that accounts for 20% of hospital-acquired infections (19). In addition, a secreted fraction having adenylyl cyclase activity and a gene homologous to known adenylyl cyclase toxins were found in *Yersinia pestis,* a bacterium that causes bubonic and pneumonic plagues (21–23). Thus, molecules that can block the action of adenylyl cyclase toxins may have a broad usage to combat illness caused by several deadly human pathogens.

Here we describe the identification of specific inhibitors of EF and CyaA among commercially available chemicals. We first docked ~200,000 molecules from the Available Chemical Directory (MDL Information Systems Inc., San Leandro, CA) in multiple orientations and conformations into the ATP binding site of EF. Twenty-four high scoring molecules were selected for experimental studies to identify those that specifically inhibit EF and CyaA compared with corresponding host adenylyl cyclases and subsequently to block the intoxication of adenocortical Y1 cells caused by edema toxin (a combination of EF and PA). This study identified a family of quinazoline compounds, the best of which specifically inhibited EF and CyaA with a $K_i$ value of 20 nM without inhibiting mammalian type I, II, and V adenylyl cyclases.

**EXPERIMENTAL PROCEDURES**

**Materials**—Compounds 2-phenylaminoadenosine, (3aR,4aS,7aR,7aS)-7-(carbzenoxylamino)-5a,4,7,7a-tetrahydro-2,2-dimethyl-1,3-benzodioxol-4-ol, and 2,7-diamino-3-cyano-4-phenyl-4-n benzopyran were purchased from Sigma; n(2,4-dinitropheno)[1,3]thiazolo[5,4-d]pyrimidine-2,7-diamine and 2-amino-4(2-furyl)-5-oxo-5,6,7,8-tetrahydro-4H-cromene-3-carbonitrile were from Bionet (Camelford, UK); FU120 and PUT74 were from Menai (Gwynedd, UK); 1608-35 was from Butt Park (Bath, UK); 6,8-dibromoquinazolin-4-ol, 5-amino-8-(trifluoromethyl)pyrido[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine-3-carbonitrile, 3-phenyl-8-(trifluoromethyl)pyrido[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, (2-amino-4,5-dimethyl-3-thienyl)(4-chlorophenyl)methane, ethyl 5-aminoquinazolino-3-carboxylate, (5-amino[1,2,3]triazolo[1,5-a]quinazolin-3-yl)morpholino methanone, n3-(4-pyridylmethyl)-5-amino[1,2,3]triazolo[1,5-a]quinazoline-3-carboxamide, 9-fluoro-5H-cromen-4(3H)pyrimidine-2-amine, 2-(3-amino-4-oxo-4H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-7-y1)thiocetic acid, 7-methoxy-1,2-dihydrobenz[e][1,2,4]triazolo[3,4-c][1,2,4]triazin-1,5-one, 8-(methylthio)4,5-dihydrothieno[3,4,5-b]benzo[1,3]isoxazol-4-carboxamide, 6H-8-difluoro-2,3-dihydro-1-pyrazolo[4,3,5-c]quinolin-3-one, 4-amino-1-hydroxy-5,5-dimethyl-2-phenyl-3-imidazolino-3-oxide, 7-chloro-1,2-dihydrobenz[e][1,2,4]triazolo[3,4-c][1,2,4]triazin-1-one, n3-ethyl-5-amino[1,2,3]triazolo[1,5-a]quinazolin-3-carboxamide, and (5-amino-7-chloro[1,2,3]triazolo[1,5-a]quinazolin-3-yl)(2-thienyl)methanone were from Maybridge (Cornwall, UK). Anthrax protective antigen was purchased from List Biological Laboratory (Campbell, CA), restriction enzymes were from New England Biolabs (Beverly, MA), and the QuikChange kit for site-directed mutagenesis was from Stratagene (La Jolla, CA). $[^{32}P]ATP$ and the Big-Dye kit for automatic DNA sequencing were from PerkinElmer Life Sciences. Mouse adrenocortical Y1 cells were obtained from ATCC. Tissue culture reagents were obtained from Invitrogen and Cambrex Bio Science Walkersville, Inc. (Walkersville, MD).

**Docking**—The Northwestern University version (24–27) of DOCK (28, 29) was used to screen the Available Chemical Directory (version 2000.2, MDL) against the $3^\text{-dATP}$ binding site of the EF$\text{CaM}$ structure (Protein Data Bank code 1K90). To prepare the site for docking, $3^\text{-dATP}$ and all water molecules were removed. The observed ytterbium ion was treated as a magnesium ion, which is a tightly bound, non-displaceable group. Protonation of enzyme residues was done with Sybyl (Tripos, St. Louis, MO). To generate docking “spheres,” which are used to orient ligand, we used both the positions of the $3^\text{-dATP}$ atoms and sphere positions identified by SPHGEN (28). Several selective spheres were labeled based on the chemical functionality of the nearby residues. The program DISTMAP was used to compute the excluded volume grid of EF (30), which is used as an initial steric filter in docking calculation. Electrostatic and van der Waals energy potential grids were calculated by DelPhi (31) and CHEMMGRID (29), respectively.

**FIG. 1.** Effect of CaM and calcium ion on adenylyl cyclase activity of EF, full-size EF, and EF3, a catalytic domain of EF. A, purified EF and EF3. 1 nM purified EF and EF3 were run on an SDS-polyacrylamide gel and stained by Coomassie Blue. EF, adenylyl cyclase assays were performed with 0.78 nM EF (open circles) and 0.28 nM EF3 (filled circles) in the presence of 1.0 nM free Ca$^{2+}$. C, adenylyl cyclase activities were measured with 0.52 nM EF (open circles) and 0.56 nM EF3 (filled circles) in the presence of 10 nM CaM. Mean $\pm$ S.E. are representative of at least two experiments.
Plus (36), and 19 molecules were selected for experimental testing as inhibitors of EF. Following initial enzyme inhibition assays, the ISIS program (MDL) was used to select five high scoring analogs of compounds 1 and 2, two initial docking “hits” that were found to inhibit EF, for testing.

Purification of EF, EF3, CyaA-N, and CaM—EF3 and CyaA-N, the catalytic domains of EF and CyaA, respectively, as well as calmodulin were purified as described previously (37, 38). To express edema factor that has a hexahistidine tag substituted for its leader peptide (amino acids 1–33) and can be delivered by anthrax-protective antigen into host cells, a plasmid, pProEx-H6-EF, was constructed as follows. The 3.2-kb EcoRI-XhoI fragment was excised from pSE42 (kindly provided by S. Leppla, National Institutes of Health) and inserted into pBluescript. A NotI site was then introduced at the sequence encoding amino acids 32–34 of EF by site-directed mutagenesis, and the mutation was confirmed by DNA sequencing. The 3.2-kb NotI-XhoI fragment encoding amino acids 35–800 of EF was subsequently moved into pProEx-H6. To make recombinant H6-EF, an N-terminal hexahistidine-tagged EF, pProEx-H6-EF was transformed into BL21(DE3) that harbored pUBS520, a plasmid that encoded tRNA for the AGA and AGG codons. The resulting cells were grown in a modified T7 medium with 50 \( \mu \)g/ml ampicillin and 25 \( \mu \)g/ml kanamycin at 30°C and harvested 19 h postinduction. The purification of EF was done by using a nickel-nitrilotriacetic acid column followed by Q-Sepharose column to yield 20 mg from each liter of Escherichia coli culture.

The protein concentrations of all recombinant proteins were determined by Bradford assay using bovine serum albumin as the standard.

Enzymatic Assays—Adenylyl cyclase activities were measured in the presence of 20 mM HEPES (pH 7.2), the indicated ATP concentration and of compounds dissolved in Me2SO. To avoid the effect of Me2SO, only 1 \( \mu \)l of the compound solution (or Me2SO as the solvent control) was added into the 100-\( \mu \)l reaction. Means \( \pm \) S.E. are representatives of at least two experiments, and specific activities of EF3 without compounds in these experiments were in the range of 0.6–1.6 ms\(^{-1}\).

### Table I

| Compound | Structure | Docking rank \( ^{a} \) | IC\(_{50}^{b} \) | Inhibition | Cell-based assay \( ^{c} \) |
|----------|-----------|------------------------|-------------|-----------|---------------------|
| 1 (173465) | ![Structure](image1) | 391 | 90\(^{b} \) | Ambiguous \( ^{a} \) | N |
| 2 (173464) | ![Structure](image2) | 328 | 70\(^{b} \) | Non-specific \( ^{d} \) | N |
| 3 (119904) | ![Structure](image3) | 412 | 60 | Specific \( ^{c} \) | Y (125 \( \mu \)M) |
| 4 (119805) | ![Structure](image4) | 2033 | >1000 | N.A. \( ^{f} \) | N |
| 5 (277898) | ![Structure](image5) | 890 | 90 | Specific | Y (125 \( \mu \)M) |
| 6 (119908) | ![Structure](image6) | 982 | 900 | N.A. \( ^{f} \) | N |
| 7 (120855) | ![Structure](image7) | 403 | 25 | Promiscuous \( ^{g} \) | N |
| 8 (177532) | ![Structure](image8) | 451 | 300 | Promiscuous | N.D. \( ^{i} \) |

\( ^{a} \) Out of 205,000 molecules docked.  
\( ^{b} \) Apparent IC\(_{50} \) values were determined in the presence of 50 \( \mu \)M ATP.  
\( ^{c} \) Showed sharp transition in the dose-response curve of EF inhibition and formation of aggregates based on dynamic light scattering.  
\( ^{d} \) Showed inhibition of \( \beta \)-lactamase activity.  
\( ^{e} \) Neither showed promiscuity in inhibiting the activity of EF nor inhibition of \( \beta \)-lactamase activity.  
\( ^{f} \) Not applicable.  
\( ^{g} \) Showed sign of promiscuous inhibition to the activity of EF.  
\( ^{h} \) Blocked the morphological change of adenocortical Y1 cells from spread to round-up morphology within 1–4 hr in response to the addition of PA and EF.  
\( ^{i} \) Not done.

Fig. 2. Effects of eight compounds on adenylyl cyclase activity of EF3. The adenylyl cyclase assay was done in the presence of 16\( \mu \)M EF3, 1 \( \mu \)M CaM, 1 \( \mu \)M free Ca\(^{2+} \), and the indicated concentrations of compounds dissolved in Me2SO. To avoid the effect of Me2SO, only 1 \( \mu \)l of the compound solution (or Me2SO as the solvent control) was added into the 100-\( \mu \)l reaction. Means \( \pm \) S.E. are representatives of at least two experiments, and specific activities of EF3 without compounds in these experiments were in the range of 0.6–1.6 ms\(^{-1}\).
Reactions were initiated either by the addition of enzyme or, if inhibitor-enzyme preincubation was being tested, by the addition of substrate. Dynamic Light Scattering—Compounds were dissolved to 20 mM in Me₂SO and diluted with filtered 50 mM pH 7.0 potassium phosphate buffer (KPi). All compounds were analyzed with a 3-watt argon-ion laser at 514.4 nm with optical systems from Brookhaven Instrument Corp. The laser power and integration times were comparable for all experiments. Calculation of mean particle diameter was performed by the cumulate analysis tool of a 400-channel BI9000AT digital autocorrelator with the last four channels used for base-line measurement. The detector angle was 90°. Three to five independent measurements were performed for each concentration of each compound at 22°C.

Cell Round-up Assay of Adrenocortical Y1 Cells—Y1 cells were maintained at 37°C with 5% CO₂ in Dulbecco’s modified Eagle’s medium/F-12 supplemented with 2.5% fetal bovine serum and 12.5% horse serum. Plates and flasks were coated with 1% gelatin before cells were plated to facilitate cell attachment and spreading. Y1 cells were plated in 96-well plates at 200 × 10⁴ cells/well and used when they reached 50–80% confluence (about 5 × 10⁵ cells/well). For the round-up assay of Y1 cells, compounds were dissolved in Me₂SO at concentrations ranging from 50 μM to 390 μM in 2-fold dilutions, and 2 μl of each concentration were added to the appropriate wells. After a 1-h incubation, EF and PA were added to 3 and 25 ng/ml final concentrations, respectively. The morphology of Y1 cells was examined after 1 h, 4 h, and overnight incubation.

Surface Plasmon Resonance Spectroscopy—The ability of EF to bind cutinase-CaM was monitored by surface plasmon resonance spectroscopy as described previously (38, 41). In brief, EF (0.24 mM–2 μM) in the binding buffer (10 mM Tris-HCl, pH 7.0, 1.0 mM EGTA, 10 mM MgCl₂, 100 mM KCl, 0.96 mM CaCl₂) was mixed with compound 3 or 5. This

**Fig. 3.** The promiscuity of compounds based on the *in vitro* adenylyl cyclase assays (A and B) and on dynamic light scattering (C and D). Adenylyl cyclase assays were performed in the same way as in Fig. 2 except that 160 pM EF3 was used in the 10× EF condition and a 10-min incubation at 20°C prior to the assay was done in the 20°C condition. Means ± S.E. are representative of at least two experiments, and specific activities of EF3 without compounds in these experiments were in the range of 1.4–2.4 ms⁻¹. Autocorrelation functions from dynamic light scattering of 100 μM compound 1 (C) and 200 μM compound 3 (D) were performed in 50 mM KP.

**Fig. 4.** Effect of compounds 3 and 5 on the morphology of Y1 cells. Pictures were taken 1 h after addition of EF and PA to final concentrations of 3 and 25 ng/ml, respectively. Y1 cells were incubated without EF and PA; with EF and PA; with EF, PA, and 250 μM compound 3; or with EF, PA, and 250 μM compound 5 as indicated.
mixture was then allowed to interact with cutinase-CaM immobilized on 2% phosphonate surface with a flow rate of 3 μl/min for 20 min, and the amount of bound EF was determined from the change of surface plasmon spectroscopic response.

RESULTS

Full-length EF (H6-EF) and the Catalytic Domain of EF (EF3) Have Similar Sensitivities to Calcium and CaM—Due to the problem in expressing the full-length EF, we have expressed and characterized the 60-kDa adenylyl cyclase domain of EF, named EF3 (37). By optimizing the expression, we now have effectively expressed and purified recombinant 90-kDa H6-EF, which contains both the catalytic domain and PA-binding domain of EF. After nickel-nitrilotriacetic acid and Q-Sepharose columns, ~20 mg of 90% pure H6-EF was obtained from each liter of E. coli culture (Fig. 1A), a 5-fold improvement over the previously reported expression and purification protocols (42). H6-EF can be stimulated by CaM with V_max and EC_{50} values identical to those of EF3 (Fig. 1B). We have recently shown that physiological calcium concentrations can promote the association between CaM and EF3 as well as directly inhibit the catalytic rate of EF3; such regulation is also found in H6-EF (Fig. 1C) (38). Thus, our data showed that the catalytic properties of EF are identical to those of EF3. For the subsequent studies, we used EF3 for the in vitro enzymatic assay to avoid the potential complication of the PA-binding domain of EF and used H6-EF for tissue culture cells where the PA-binding domain is required for EF to enter into cells.

Identification of Compounds That Can Inhibit the Catalytic Domain of EF—Our goal was to identify low molecular weight molecules that can specifically inhibit adenylyl cyclase toxins without affecting host adenylyl cyclases and block the cellular intoxication by edema toxin (PA and EF). To do so, we targeted our structure-based inhibitor discovery to the catalytic site of EF. The 3'-dATP binding site of the EF-CaM complex was screened against a data base of 205,226 small molecules. On average, each compound was sampled in 447 orientations and 294 conformations, and overall 2.7 \times 10^{10} configurations were scored. Top scoring molecules were visually examined in the context of the binding site, and 19 compounds were initially chosen based on electrostatic or polar complementarity as well as favorable nonpolar interactions. These compounds were purchased and tested for their ability to inhibit adenylyl cyclase activity of EF3, a recombinant protein containing only the catalytic portion of EF. Two pyrido[2,3-e][1,2,3]triazolo[1,5-
Inhibitor of Anthrax Edema Factor

25995

a pyrimidine-5-arnes (compounds 1 and 2) and one phenylmethanone (compound 8) were found to have IC\(_{50}\) values lower than 300 \(\mu\)M (Fig. 2 and Table I). Five high scoring analogs (compounds 3–7) of compounds 1 and 2, which have IC\(_{50}\) values of about 100 \(\mu\)M, were picked from the Available Chemical Directory based on chemical similarity and were also tested for inhibition of EF (Fig. 2 and Table I). Three of these (compounds 3, 5, and 7) have IC\(_{50}\) values lower than 100 \(\mu\)M.

Filtering the Active Compounds by Promiscuity Assays—Chemical compounds may form aggregates that promiscuously inhibit the activity of EF instead of specifically occupying its active site; such phenomena have been observed for many inhibitors from virtual and high throughput screening as well as for protein kinases (43–45). To eliminate the compounds with this unwanted effect, we first investigated the effect of preincubation of compounds with EF (Fig. 3, A and B; not shown for compound 8). We found that compounds 7 and 8 had reduced IC\(_{50}\) values, an indication of promiscuous inhibition. In addition, the same set of compounds also had increased IC\(_{50}\) values when 10-fold more EF was used, which also suggested promiscuous inhibition. We then investigated the activities of compounds 1, 2, 3, and 5 against a completely unrelated enzyme, \(\beta\)-lactamase. Compounds 1, 3, and 5 at 200–300 \(\mu\)M concentrations did not inhibit \(\beta\)-lactamase and showed no preincubation effect, while compound 2 at 70 \(\mu\)M almost completely inhibited \(\beta\)-lactamase activity. The inhibition of \(\beta\)-lactamase by compound 2 increased after preincubation and decreased when the enzyme concentration was raised by 10-fold (data not shown). We then used dynamic light scattering experiments to test whether compounds 1, 3, and 5 can form aggregates, which is a characteristic of some promiscuous inhibitors (43, 45). Compound 1 at a concentration comparable to its IC\(_{50}\) for EF showed high intensity scatter that decayed on the 1,000–100,000 \(\mu\)s time scale, suggesting that particles larger than 1 \(\mu\)m in diameter were present (Fig. 3C). Compounds 3 and 5, at up to 200 \(\mu\)M, gave low intensity, poorly defined autocorrelation functions, consistent with the absence of particles (Fig. 3D, not shown for compound 5). These phenomena are consistent with the notion that compounds 3 and 5 are classical, specific inhibitors of EF, while part of the inhibition of EF by compounds 1, 2, 7, and 8 may be caused by the aggregation-based mechanism (43, 45).

Compounds 3 and 5 Block Round-up of Adrenocortical Y1 Cells Induced by EF and PA—The increase of intracellular cAMP can cause actin-cytoskeleton rearrangement and rounding up of mouse adrenocortical Y1 cells (46); such changes are commonly induced by bacterial toxins (47). To monitor whether compounds 1–7 can block the production of cAMP by EF, we took advantage of the rapid morphological change (within 1 h) seen in mouse adrenocortical Y1 cells in response to agents that increase cAMP. When H6-EF and PA were added to cells together, we observed the expected round-up of Y1 cells (Fig. 4). However, neither H6-EF nor PA alone also could induce round-up of Y1 cells (not shown). We then tested compounds 1–7 in Table I and found that only compounds 3 and 5 could block the cAMP-induced round-up of Y1 cells at concentrations of 125 \(\mu\)M and above (Fig. 4 and Table I). The other compounds had no effect on the round-up of Y1 cells even at a concentration of 1 mM (data not shown). These data together with the results above led us to focus our subsequent analysis on compounds 3 and 5.

Specificity of Compounds 3 and 5—We then tested the specificity of compounds 3 and 5 on CyaA-N, the adenyl cyclase domain of CyaA, which is an exotoxin secreted by \(B.\) pertussis (Fig. 5, A and B). We found that compounds 3 and 5 inhibited CaM-activated activity of CyaA-N with IC\(_{50}\) values of 40 and 80 \(\mu\)M, respectively. There are nine isoforms of membrane-bound adenyl cyclase found in mammals (48). We expressed three of them (type I, II, and V adenyl cyclase) using SF9 cells and tested whether compounds 3 and 5 could modulate the activity of these enzymes (Fig. 5, C and D). All three enzymes are activated by forskolin and recombinant \(G_s\), the \(\alpha\) subunit of the stimulatory \(G\) protein \(G_s\). We found that, up to 500 \(\mu\)M, compound 3 reduced by 20–45% the activity of all three mammalian adenyl cyclases, while compound 5 only marginally reduced the activities of those three enzymes.

Mechanism of Inhibition of EF by Compounds 3 and 5—We also examined the mechanism of how compounds 3 and 5 inhibit the catalytic activity of EF3 (Fig. 6). By varying substrate and inhibitor concentrations, the kinetics of inhibition by compounds 3 and 5 were found to fit well for a competitive inhibition mechanism, indicating that they compete directly with the binding of ATP (Fig. 6A, data not shown for compound 3). The estimated \(K_i\) values were 50 and 20 \(\mu\)M for compounds 3 and 5, respectively. Both EF and CyaA are activated by CaM. By loading a cutinase-CaM fusion protein to a self-assembled monolayer using active site-directed immobilization, we have used surface plasmon resonance spectroscopy to show that EF can specifically bind to the immobilized CaM in a calcium-de-
independent manner (38). Using this method, we then examined whether compounds 3 and 5 affected the interaction between EF and CaM (Fig. 6B). We found that the addition of compounds 3 and 5 did not change the affinity of EF to CaM at 10 μM free Ca<sup>2+</sup>. This result indicated that these compounds did not affect the interaction between EF and CaM.

### DISCUSSION

Compound 5 is a novel, specific inhibitor of adenylyl cyclase toxins from *B. anthracis* and *B. pertussis*. It blocks the morphological change in Y1 cells induced by edema toxin without the inhibition of mammalian type I, II, and V adenylyl cyclases. Despite its modest affinity (20 μM), its specificity and activity in cell culture make it a potentially good lead for an antitoxin agent against anthrax and whooping cough. Thus, it is appropriate to consider how the affinity of the inhibitor might be improved. In the absence of a crystal structure of an EF-inhibitor complex, we turned to the docking-predicted geometries to understand the binding of this compound. Based on our docking model, compound 5 overlaps primarily with the adenine group of the 3'-dATP structure, consistent with our data that the mechanism of inhibition is competitive (Fig. 7A). The quinazolino ring fragment fits snugly into the pocket where the adenine group binds where it would form the same three hydrogen bonds with the backbone atoms of residues Thr-579 and Thr-548 as the adenine group does (distances are between 3.0 and 3.4 Å). In addition, compound 5 appears to form a hydrogen bond with the Oy of Thr-548 through its ester oxygen atom (distance is 2.8 Å). The ethoxyl group of compound 5 fits into a shallow groove on the enzyme surface.

Our model suggests that it will be possible to improve the affinity of this compound to EF without compromising the specificity. EF binds the ribose moiety of ATP in a manner that differs significantly from mAC. His-351 of EF is believed to interact with the 3'-OH of the ribose, while a catalytic metal is proposed to serve as the catalytic base. In addition, a hydrophobic pocket centered around Phe-586 of EF has also been shown to play a vital role in the binding of 3'-anthranyl group of the 2'-deoxy-3'-anthranyl-ATP of EF-CaM complex (38). This pocket is proximal to the putative binding site of compound 5 but is not currently used by this compound; derivatives might be able to do so, thus improving affinity. Finally, the highly positively charged pocket formed by a catalytic metal and a group of basic amino acids (Arg-329, Lys-346, Lys-353, and Lys-372), which interacts with the phosphate groups of the nucleotide substrate, is not exploited by compound 5 (6).

Compound 5 represents the first non-nucleoside-based inhibitor of adenylyl cyclase toxins. It is dissimilar from nucleoside analogs and NKY80, a previously described non-nucleoside-based inhibitor of host adenylyl cyclases (49, 50). Several triazolo[1,5-a]quinoxaline compounds, which are structurally similar to compound 5 (5-aminopyrazolo[1,5-a]quinoxaline-3-carboxylate) have been synthesized and characterized recently (51). A subset of triazolo[1,5-a]quinoxaline compounds is found to act as antagonists of the adenosine receptor and the benzodiazepine receptor. Together with our result, this suggests that azolo[1,5-a]quinoxalines may be well suited to mimic adenine.

Our data show that substituting the ester of compound 5 with a secondary amide (compound 6) decreased the affinity by 10-fold. The presence of an intramolecular hydrogen bond in compound 6 (Fig. 7B) may favor a conformation that poorly fits the catalytic site of EF. As a tertiary amide, compound 3 cannot form this intramolecular hydrogen bond and adopts a conformation better suited to the binding site. The lack of activity of compound 4, which also has a secondary amide, is consistent with this view. Other possibilities such as the difference in solvation energy may also explain our observation. Further structure-activity studies are required to resolve this issue.

Our data also show that inhibitors against the catalytic site of EF from *B. anthracis* can be identified by structure-based inhibitor discovery. The hit rate in this computational approach, about 5%, is consistent with a recent docking screen for novel inhibitors of β-lactamase as is the potency of the inhibitors discovered (52). The hit rate is almost 10-fold lower than that in a large scale effort against a tyrosine phosphatase (53).
and is lower than that found by several other docking programs (for a recent review, see Ref. 54). However, we have gone to considerable effort to consider only non-promiscuous, biologically active molecules as “true” hits, which diminished their numbers. We note that promiscuous, aggregating small molecules appear to be relatively common in hit lists from both virtual and high throughput screening (44), and even widely used biological reagents such as kinase inhibitors rottlerin (against protein kinase C-δ) and K-252c (against cAMP-dependent protein kinase and protein kinase C) can act this way at micromolar concentrations (45). Therefore, care must be taken to exclude these promiscuous aggregators from hit lists in inhibitor discovery projects.

Acknowledgments—We thank MDL for use of the Available Chemical Directory data base and the program ISIS and OpenEye Software for the conformation generation program Omega. We thank the Northwestern Keck Biophysics Facility for the dynamic light scattering instrument.

REFERENCES

1. Ingelby, T. V., O’Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Etzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., McDade, J., Osterholm, M. T., Parker, G., Perl, T. M., Russell, P. K., and Tonat, K. (2002) J. Am. Med. Assoc. 287, 2236–2252

2. Mourez, M., Lacy, D. B., Cunningham, K., Legmann, R., Sellman, B. R., Mogridge, J., and Collier, R. J. (2002) Trends Microbiol. 10, 287–293

3. Bradley, A., Mogridge, J., Mourouzis, R., Collier, R. J., and Young, J. A. (2001) Nature 414, 225–229

4. Mogridge, J., Cunningham, K., and Collier, R. J. (2002) Biochemistry 41, 1079–1092

5. Miller, C. J., Elliott, J. L., and Collier, R. J. (1999) Biochemistry 38, 10432–10441

6. Drum, C. I., Yan, S. Z., Bard, J., Shen, Y., Lu, D., Soelaiman, S., Grabarek, Z., Bohm, A., and Tang, W. J. (2002) Nature 415, 396–402

7. Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D., and Vande Woude, G. F. (1988) Science 290, 734–737

8. Park, J. M., Greten, F. R., Li, Z. W., and Karin, M. (2002) Science 297, 721–724

9. Mock, M., and Fouet, A. (2001) Annu. Rev. Microbiol. 55, 647–671

10. Pannifer, A., Wong, T. Y., Schwarzenbacher, R., Renatus, M., Petosa, C., Bienkowski, J., Lacy, D. B., Collier, R. J., Park, S., Leppla, S. H., Hanna, P. C., and Liddington, R. C. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13904–13909

11. Petosa, C., Collier, R. J., and Klimpel, K. R. (2002) Inhibitor of Anthrax Edema Factor. BD. 7, 1781–1786

12. Shevchenko, L. A., and Mishankin, B. N. (1987) Zh. Mikrobiol. Epidemiol. Immunobiol. 7, 59–63

13. Parkhill, J., Wren, B. W., Thomson, N. R., Tibrab, R. W., Holden, M. T., Prentice, M. B., Sebastian, J., James, K. D., Churcher, C., Munగk, K. L., Baker, S., Basham, D., Bentley, S. D., Brooks, K., Cerdeno-Tarraga, A. M., Chillingworth, T., Cronin, A., Davies, R. M., Davis, P., Dougan, G., Feltwell, T., Hamlin, N., Holroyd, S., Jagels, K., Karlsbyav, A. Y., Leather, S., Moule, S., Oyston, P. C., Quail, M., Rutherford, K., Simmons, M., Skilton, J., Stevens, K., Whitehead, S., and Barrett, B. G. (2001) Nature 415, 523–527

14. Borberg, D. M., and Shoichet, B. K. (1998) Protein Sci. 7, 938–950

15. Lecomte, T., and Roux, B. (2002) Protein Sci. 11, 1093–1109

16. Shevchenko, B. K., Leach, A. R., and Kuntz, I. D. (1999) Proteins 34, 4–16

17. Shen, Y., Lee, Y. S., Soelaiman, S., Bergersen, P., Lu, D., Chen, A., Beckingham, K., Grabarek, Z., and Tang, W. J. (2002) J. Biol. Chem. 275, 36334–36340

18. Shen, Y., Lee, Y. S., Soelaiman, S., Bergersen, P., Lu, D., Chen, A., Beckingham, K., Grabarek, Z., Mrksich, M., and Tang, W. J. (2002) EMBO J. 21, 761–772

19. Brossier, F., Weber-Levy, M., Mock, M., and Sirard, J. C. (2000) Trends Microbiol. 8, 171–176

20. Goodwin, M. S., and Weiss, A. A. (1990) Infect. Immun. 58, 3445–3447

21. Michankin, B. N., Chevchenko, I. A., and Asseeva, L. E. (1992) Bull. Soc. Pathol. Exot. 85, 17–21

22. Abagyan, R., and Totrov, M. (2001) J. Biol. Chem. 276, 47785–47793

23. Bertelli, L., Biagi, G., Gori, I., Lavi, O., Manera, C., Scarrtoni, Y., Lucacchini, A., Giannaccini, G., and Barili, P. L. (2000) Eur. J. Med. Chem. 35, 333–341

24. Powers, R. A., Morandi, F., and Shoichet, B. K. (2002) Structure (Camb.) 10, 1031–1034

25. Doman, T. N., McGovern, S. L., Witherbee, B. J., Kasten, T. P., Kurumait, R., Stallings, W. C., Connolly, D. B., and Shoichet, B. K. (2002) Proteins 48, 1082–1099
